

WILSONS DRUG & DEVICE CONFERENCE PRESENTATION

PERTH, Australia and SAN FRANCISCO, California – 26 October 2023

PYC Therapeutics Limited (ASX:PYC) is pleased to provide a copy of the presentation that will be given by PYC's CEO, Dr Rohan Hockings, at the Wilsons Drug & Device Conference, 26 October 2023.

About PYC Therapeutics

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood (RP11) into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit <u>pyctx.com</u>, or follow us on <u>LinkedIn</u>.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

^{2.} Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS: INVESTORS and MEDIA info@pyctx.com



Life-changing science

Wilsons Healthcare Conference

PYC Therapeutic

October 2023

Disclaimer

The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Executive Summary



- RNA therapeutics are one of the fastest growing modalities within the pharmaceutical industry
- Delivery remains the single greatest obstacle to realising the full potential of this class of drug
- PYC's drug delivery technology overcomes this challenge enabling the Company to launch multiple first-in-class and potentially disease-modifying drugs into the clinic
- PYC's wholly-owned pipeline of RNA drugs are set for data read-outs across multiple human trials over the coming 36 months¹
- Each drug targets an addressable market of \$1-5 billion p.a.² in indications with the highest probability of success in human trials³

1. Subject to regulatory approval

^{2.} Market size is projected by multiplying patient prevalence per indication by the median orphan drug price of US\$150k p.a. EvaluatePharma. Orphan Drug Report. 2019

B. Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank. doi: https://doi.org/10.1101/2020.11.02.20222232



RNA therapies are set for

"extreme acceleration"

Sanofi¹



But they have an Achilles heel – delivering sufficient drug inside the target cell



"While everybody else was so hyped and giving Nobel Prizes for CRISPR and all that, we realized those weren't really the limitations

The limitations were really delivery"


George Yancopoulos, President and CSO, Regeneron

PYC's <u>non-viral</u> drug delivery platform extends the reach of RNA therapies to new disease indications




PYC achieves ~100x the target engagement of the 'naked' RNA drug in vivo'

PYC combines existing RNA drug design technology with its proprietary delivery platform to create potent and precise RNA drugs





PYC's delivery platform is used to assist the RNA drug reach its target inside the target cell



PYC's drug delivery technology opens up new possibilities in areas of major unmet patient need








A single safe and welltolerated dose of PYC's second drug candidate increases expression of the target protein (stained in red) in Non-Human Primates.

Insufficient expression of this protein causes a blinding eye disease of childhood


PYC's drug candidates have already demonstrated efficacy in 3D models derived from patients with the target disease



PYC-001 treatment corrects mitochondrial structural defects in ADOA patient-derived iPSC-RGCs



Nuclei/Mitochondria (TOMM20)



Bar graph represents mean+SD @ day 7 PPMO incubation, Patient derived IPSC-RGC harbouring OPA1 c.2608delA mutation, n=1 biological replicate, 3 technical replicate, Minimum of 406 cells used for mitochondrial analysis. Student's *t* test ****p<0.0001.

https://news.alnylam.com/rnai/articles/harnessing-human-genetics-power-next-wave-rnai-therapeutics

100

40 35.2 27.4 30 20

Probability of Success (POS) by Phase Transition

Drugs targeting diseases caused by single gene mutations are much more likely to succeed in clinical development

High-Yield Productivity of Alnylam RNAi Therapeutics Platform

87.5 90 85.7 85.7 80 69.2 70 Percent POS 64.3 63.7 60 50 44.5 38.6 10.3 10 0 % POS. Phase 1 to 2 % POS. Phase 2 to 3 % POS. Phase 3 % POS, Cumulative

Analysis as of November 2021; Past rates of Alnylam and industry respectively may not be predictive of the future

² Alnylam programs biomarker-driven at all stages of development (100%); figures include Alnylam-originated molecules now being developed by partners 3 Wong et al., Biostatistics (2019) 20, 2, pp. 273-286

Alnylam²

Comparison of Historical Industry Metrics to Alnylam Portfolio¹

© 2023 Alnylam Pharmaceuticals - All Rights Reserved

Industry (overall)³

Genetic Validation of Targets Has Yielded Success Rates >6x Industry Avg.

Industry (biomarker-driven programs)³

PYC THERAPEUTICS

9

6

PYC has multiple first-in-class assets that address the root cause of a major unmet patient need



"It's hard for me to think of a higher level of target validation, at least for an unapproved drug, than human genetic validation"

"What matters is having really high-quality projects rooted in human biology with the right tool"

David Altshuler, Vertex Pharmaceuticals CSO

These assets will provide **5 human data read-outs** within the next 36 months¹



